Media Coverage
Media Coverage
Press Contacts: Erik Cummins, Matt Hyams, Olivia Thomas
05.11.22
A team of Pillsbury lawyers represented the investors of a revenue interest financing agreement with Phathom Pharmaceuticals Inc., a biopharmaceutical company with a focus on the development and commercialization of novel treatments for gastrointestinal diseases and disorders, in an effort to back the company’s esophagitis drug. The agreement provides for an upfront $100 million cash payment and an additional $160 million cash payment upon FDA approval of vonoprazan for treatment of erosive esophagitis.
Pillsbury represented investors including NovaQuest Capital Management LLC, Sagard Holdings Manager LP and Hercules Capital Inc. Morgan Stanley & Co. LLC acted as sole structuring agent on the transaction.
The team was led by Jeff Delaney, who leads Pillsbury’s firmwide Corporate and Securities practice section, along with David Baxter, who is the co-leader of Pillsbury’s Capital Markets Group, Finance partner Michael Reese, Tax partner Harsha Reddy, Corporate counsel Stephanie Langan and associate Mackenzie Pantoja, all in New York.